medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2004; 3 (3)


Nonalcoholic fatty liver disease

Grant LM, Lisker-Melman M

Idioma: Ingles.
Referencias bibliográficas: 66
Paginas: 93-99
Archivo PDF: 113.57 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20(6): 594-8.

  2. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434-8.

  3. Bacon BR, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107(4): 1103-9.

  4. Sathya P, Martin S, Alvarez F. Nonalcoholic fatty liver disease (NAFLD) in children. Curr Opin Pediatr 2002; 14(5): 593-600.

  5. Marchesini G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50(8): 1844-50.

  6. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000; 75(7): 733-9.

  7. Falck-Ytter Y, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21(1): 17-26.

  8. Marcos A, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000; 69(11): 2410-5.

  9. Hilden M, et al. Liver histology in a ‘normal’ population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12(5): 593-7.

  10. Ground KE. Liver pathology in aircrew. Aviat Space Environ Med 1982; 53(1): 14-8.

  11. Kopelman PG. Obesity as a medical problem. Nature 2000; 404(6778): 635-43.

  12. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346(8): 591-602.

  13. Mokdad AH, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289(1): 76-9.

  14. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997; 146(3): 214-22.

  15. Resnick HE, et al. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health 2000; 54(8): 596-602.

  16. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12(5): 1106-10.

  17. Bellentani S, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132(2): 112-7.

  18. Powell EE, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11(1): 74-80.

  19. Moran JR, et al. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 1983; 78(6): 374-7.

  20. Baldridge AD, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127(5): 700-4.

  21. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123(5): 1705-25.

  22. Bellentani S, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41(6): 845-50.

  23. Becker U, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23(5): 1025-9.

  24. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94(4): 1018-22.

  25. Yajima Y, et al. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983; 139(1): 43-50.

  26. Jacobs JE, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol 1998; 171(3): 659-64.

  27. Saadeh S, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123(3): 745-50.

  28. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21(1): 71-80.

  29. Longo,R, et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993; 28(4): 297-302.

  30. Petersen KF, et al. Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy. Hepatology 1996; 24(1): 114-7.

  31. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21(1): 3-16.

  32. Younossi ZM, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11(6): 560-5.

  33. Brunt EM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94(9): 2467-74.

  34. Teli MR, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22(6): 1714-9.

  35. Angulo P, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30(6): 1356-62.

  36. Matteoni CA, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116(6): 1413-9.

  37. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121(1): 91-100.

  38. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340(10): 745-50.

  39. Marrero JA, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36(6): 1349-54.

  40. Shimada M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37(1): 154-60.

  41. Bugianesi E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123(1): 134-40.

  42. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17 Suppl: S186-90.

  43. Harrison SA, et al. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002; 97(11): 2714-24.

  44. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114(4): 842-5.

  45. Day CP. Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going? Gut 2002; 50(5): 585-8.

  46. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21(1): 27-41.

  47. Sanyal AJ, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120(5): 1183-92.

  48. Pessayre D, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21(1): 57-69.

  49. Weltman MD, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27(1): 128-33.

  50. Andersen T, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12(2): 224-9.

  51. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99(5): 1408-13.

  52. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158(17): 1855-67.

  53. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123(3): 882-932.

  54. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 2001; 35(1): 134-46.

  55. Laurin J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23(6): 1464-7.

  56. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21(1): 81-8.

  57. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136(6): 734-8.

  58. Lin HZ, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6(9): 998-1003.

  59. Marchesini G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358(9285): 893-4.

  60. Abdelmalek MF, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96(9): 2711-7.

  61. Miglio F, et al. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000; 50(8): 722-7.

  62. Okan Gulbahar, ZAK, Galip Ersoz, Ulus S Akarea, Ahmet Musoglu. Treatment of Non-alcoholic Steatohepatitis with N-Acetylcystein. Gastroenterology 2000; 118: A1444 (Abstract).

  63. (http://www.OPTN.org). 2003.

  64. Ong J, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7(9): 797-801.

  65. Contos MJ, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7(4): 363-73.

  66. Kim WR, et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62(12): 1802-5.




2020     |     www.medigraphic.com